SeaBird Exploration Limited to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in SeaBird Exploration Limited to listing on the SMB List of Oslo Børs.
The Board stipulated that prior to the first day of listing the company must satisfy the requirements for the number of holders of one round lot or more of the company's shares set out in the Oslo Børs Listing Rules (minimum of 100 holders of at least one round lot), and for more than 25% of the shares to be admitted to listing to be held by the general public. In addition, the company must publish a listing prospectus approved by Oslo Børs prior to the first day of listing, and must raise at least USD 20 million of new equity through its planned share issue.
The Board authorised the President of Oslo Børs to fix the date of the first day of listing, which is to be no later than 12 May 2006.
About SeaBird
SeaBird Exploration Limited (BVI) "SeaBird" is a global provider of 2D and 3D seismic data and associated products and services to the oil and gas industry. SeaBird specializes in high quality operations within the high end of the source vessel and 2D market, as well as in the shallow water 2D/3D market. Main focus for the company is proprietary seismic surveys (contract seismic). SeaBird does not have a multi-client data library. Main success criteria for the company are an unrelenting focus on Quality, Health, Safety and Environment (QHSE), combined with efficient collection of high quality seismic data. SeaBird operates a seismic fleet of 4 vessels with two additional vessels under conversion with expected completion during the first half of 2006.
Navamedic ASA to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in Navamedic ASA to listing on the SMB List of Oslo Børs.
The Board stipulated that prior to the first day of listing the company must publish a listing prospectus approved by Oslo Børs.
The Board authorised the President of Oslo Børs to fix the date of the first day of listing, which is to be no later than 12 May 2006.
About Navamedic
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient against osteoarthritis with a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world’s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company’s products will be sold through a network of sales, marketing and distribution partners. Navamedic’s product Glucomed® has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.
Dolphin Interconnect Solutions ASA to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in Dolphin Interconnect Solutions ASA to listing on the SMB List of Oslo Børs.
The Board stipulated that prior to the first day of listing the company must publish a listing prospectus approved by Oslo Børs.
The Board authorised the President of Oslo Børs to fix the date of the first day of listing, which is to be no later than 12 May 2006.
About Dolphin Interconnect Solutions
Dolphin Interconnect Solutions ASA is a world leading computer interconnect company. Components produced by Dolphin are used in highly demanding solutions ranging from databases to the last generation of 3 dimensional Ultrasound Imaging machines and aircraf mission computers.
Headquartered in Oslo, Norway, Dolphin has been a recognised player in the computer industry for the last 15 years and have long standing business relations with several dominating companies in the computer industry.
Fondsfinans ASA fined for a breach of the Stock Exchange Regulations and the Norex Member Rules (NMR)
The Board of Oslo Børs resolved to impose a violation charge of NOK 100,000 on Fondsfinans ASA, cf. NMR 4.11.9 and Section 25-8 of the Stock Exchange Regulations, for a breach of Section 13-3, second paragraph, of the Stock Exchange Regulations and of NMR 4.6.1 and 4.6.2.
The background for the violation charge is that on a specific occasion Fondsfinans entered a buy order in the Oslo Børs trading system on behalf of a customer that did not reflect the actual market value of the listed company, with the intention of changing the value of the customer's shareholding. Fondsfinans was aware of the customer's intention when it entered the order, which caused the closing price of the share in question to be almost 15 % higher.
This decision can be appealed to the Stock Exchange Appeals Committee. Any appeal must be submitted within two weeks.
